Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133966 | 1.00 | KMT2A (0.58) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL1133856 | 0.84 | KMT2A (0.57) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL28292088 | 0.81 | KMT2A (0.50) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL13143432 | 0.81 | KMT2A (0.57) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL965165 | 0.81 | KMT2A (0.57) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL1133971 | 0.81 | KMT2A (0.57) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL1133853 | 0.81 | KMT2A (0.53) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL1133955 | 0.81 | KMT2A (0.53) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL1133877 | 0.80 | KMT2A (0.51) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL12229292 | 0.80 | TDP1 (0.51) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303516-B2 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | EGETIS THERAPEUTICS AB (SE) | 2025-05-20 | — | — | US | disclosed |
| US-11987834-B2 | Acetaminophen adducts and methods of use thereof | BIOVENTURES, LLC (US) | 2024-05-21 | — | — | US | disclosed |
| US-11566081-B2 | Anti-acetaminophen antibodies and acetaminophen protein adducts | BIOVENTURES, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220133739-A1 | METHODS AND FORMULATIONS FOR TREATMENT OF AND/OR PROTECTION AGAINST ACUTE LIVER FAILURE AND OTHER HEPATOTOXIC CONDITIONS | EGETIS THERAPEUTICS AB (SE) | 2022-05-05 | — | — | US | disclosed |
| EP-3842040-B1 | METHODS AND FORMULATIONS FOR TREATMENT OF AND/OR PROTECTION AGAINST ACUTE LIVER FAILURE AND OTHER HEPATOTOXIC CONDITIONS | EGETIS THERAPEUTICS AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| US-11260060-B2 | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions | EGETIS THERAPEUTICS AB (SE) | 2022-03-01 | — | — | US | disclosed |
| EP-3227681-B1 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | BIOVENTURES LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200131278-A1 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS | BIOVENTURES LLC (US) | 2020-04-30 | — | — | US | disclosed |
| US-10570216-B2 | Anti-acetaminophen antibodies and acetaminophen protein adducts | BIOVENTURES, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190300931-A1 | ACETAMINOPHEN ADDUCTS AND METHODS OF USE THEREOF | BIOVENTURES, LLC | 2019-10-03 | — | — | US | disclosed |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | ACORDA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| CN-102149412-A | Hepatoprotectant acetaminophen mutual prodrugs | NEUROGESX INC | 2011-08-10 | — | — | CN | disclosed |
| EP-2285419-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | Neurogesx, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2277040-A1 | ACETAMINOPHEN-PROTEIN ADDUCT ASSAY DEVICE AND METHOD | The Board of Trustees of The University of Arkansas (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009143299-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009131998-A1 | ACETAMINOPHEN-PROTEIN ADDUCT ASSAY DEVICE AND METHOD | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090263839-A1 | ACETAMINOPHEN-PROTEIN ADDUCT ASSAY DEVICE AND METHOD | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2009-10-22 | — | — | US | disclosed |
| CN-1556694-A | Method for producing aqueous preparations of oxidation-sensitive active ingredients | ���չ�˾ | 2004-12-22 | — | — | CN | disclosed |
| CN-1328463-A | Use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors for treatment of hapatitis C type virus and other togavirus infections | HOLLIS EDEN PHARMACEUTICALS (US) | 2001-12-26 | — | — | CN | disclosed |
| US-4424150-A | Acetaminophen analogs, antigens, and antibodies | SYVA COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | KMT2A 4597/4885MEN1 4430/4885HSD17B10 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.